Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Pharmacogenomics of cisplatin-induced ototoxicity.

Mukherjea D, Rybak LP.

Pharmacogenomics. 2011 Jul;12(7):1039-50. doi: 10.2217/pgs.11.48. Review.

2.

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium.

Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Erratum in: Nat Genet. 2013 May;45(5):578.

PMID:
19898482
3.

Challenges in interpreting the evidence for genetic predictors of ototoxicity.

Ratain MJ, Cox NJ, Henderson TO.

Clin Pharmacol Ther. 2013 Dec;94(6):631-5. doi: 10.1038/clpt.2013.178.

PMID:
24241639
4.

Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.

Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U, Pakakasama S, Hongeng S.

J Pediatr Hematol Oncol. 2013 May;35(4):e138-43. doi: 10.1097/MPH.0b013e3182707fc5.

PMID:
23274376
5.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW.

PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.

6.

Genetic markers of cisplatin-induced hearing loss in children.

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.

PMID:
25141953
7.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. No abstract available.

PMID:
24193170
8.

[Genetic background of cisplatin induced ototoxicity].

Jurajda M, Talach T, Kostřica R, Lakomý R, Kocák I, Cvanová M.

Klin Onkol. 2012;25(3):184-7. Czech.

PMID:
22724567
9.

Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.

Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG.

Clin Pharmacol Ther. 2014 Aug;96(2):156-7. doi: 10.1038/clpt.2014.67. Epub 2014 Mar 18. No abstract available.

PMID:
24642735
10.

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR.

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22. No abstract available.

PMID:
24755913
11.

Genetics of cisplatin ototoxicity: confirming the unexplained?

Boddy AV.

Clin Pharmacol Ther. 2013 Aug;94(2):198-200. doi: 10.1038/clpt.2013.116.

PMID:
23872836
12.

The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.

Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, E S, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF.

Clin Pharmacol Ther. 2013 Aug;94(2):252-9. doi: 10.1038/clpt.2013.121. Epub 2013 Jun 11.

13.

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Ther Drug Monit. 2016 Aug;38(4):423-31. doi: 10.1097/FTD.0000000000000298. Review.

14.

[Ototoxicity of cisplatin].

Kitoh R, Usami S.

Nihon Rinsho. 2015 Feb;73 Suppl 2:480-5. Japanese. No abstract available.

PMID:
25831807
15.

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.

Nat Genet. 2015 Mar;47(3):263-6. doi: 10.1038/ng.3217. Epub 2015 Feb 9. Erratum in: Nat Genet. 2015 Apr;47(4):423.

16.

Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.

Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD.

J Clin Oncol. 2007 Feb 20;25(6):708-14. Epub 2007 Jan 16.

PMID:
17228018
17.

Economic impact of a genetic test for cisplatin-induced ototoxicity.

Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, Carleton B.

Pharmacogenomics J. 2012 Jun;12(3):205-13. doi: 10.1038/tpj.2011.15. Epub 2011 Apr 19. Erratum in: Pharmacogenomics J. 2012 Aug;12(4):359.

PMID:
21502965
18.

Cisplatin ototoxicity and protection: clinical and experimental studies.

Rybak LP, Mukherjea D, Jajoo S, Ramkumar V.

Tohoku J Exp Med. 2009 Nov;219(3):177-86. Review.

19.

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.

Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8. doi: 10.1002/pbc.24138. Epub 2012 Mar 19.

20.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

PMID:
28448657

Supplemental Content

Support Center